期刊文献+

泊洛沙姆在全自动血液分析仪鞘液中的应用

Use of Poloxamex of Self-made Sheath Reagent for Fully Automatic Hemocyte Analyzer
下载PDF
导出
摘要 目的:研究泊洛沙姆(Poloxamex)在SE-9000全自动血液分析仪用自制鞘液中的应用。方法:用优选出的泊洛沙姆最佳浓度及其它成分自制成试验鞘液,对进口配套的全血质控物进行准确度、精密度分析,以此评价自制鞘液的性能。结果:含有泊洛沙姆成分的自制试验鞘液,对进口配套全血质控物测得的各项质量控制指标,其均值WBC:7.09G/L,RBC:4.39T/L,Hb:131g/L,HCT:38.5L/L,PLT:227G/L,MCV:87.7fl,MCH:29.9pg,MCHC:341g/L,均处于质控物允许范围内;其标准差和变异系数分别是WBC:0.16,2.3;RBC:0.05,1.1;Hb:1.15,0.88;HCT:0.34,0.88;PLT:6.6,2.9;MCV:0.44,0.5;MVH:0.26,0.87;MCHC:2.6,0.76,均低于仪器生产厂家和CLIA'88的要求;自制试验鞘液的空白背景计数值WBC:0.05G/L,RBC:0,Hb:0,PLT:3G/L,IMI:0,DIFF:0,EO:0,BASO:0,均低于仪器生产厂家的限定值。结论:含有泊洛沙姆成分的自制试验鞘液,其性能符合仪器生产厂家和CLIA'88的质量控制要求,能替代国外同类产品用于SE-9000全自动血液分析仪的配套使用。 Objective. To investigate use of poloxamex of self-made sheath reagent for fully automatic hemocyte analyzer. Methods. A series of comparisons between the self-made sheath reagent and imported reagents were carried out. Results. The value of WBC, RBC, Hb, HCT, PLT, MCV, MCH, MCHC was 7. 09G/L, 4. 39T/L, 131 g/L, 38. 5L/L, 227G/L, 87. 7 fl, 29. 9 pg, 341 g/L, respectively, was within the working range of the criteria of quality control. The standard deviation and variance coefficient were lower than the requirements of the manufacturer and Clinical Laboratory Improvement Amendment 88, respectively. The countable value met the requirements of the manufacturer. Conclusions. The self-made sheath reagents can be used to replace the imported reagent for SE-9000 fully automatic hemocyte analyzer.
出处 《数理医药学杂志》 2007年第3期329-331,共3页 Journal of Mathematical Medicine
关键词 泊洛沙姆 鞘液 质量控制 poloxamex sheath quality control
  • 相关文献

参考文献4

二级参考文献21

  • 1郭建芬,李广元,翁其亮,王广生.去甲斑蝥素抗白血病作用──细胞毒作用[J].西北药学杂志,1994,9(3):121-123. 被引量:13
  • 2Scholes P D,Coombers A G A,Illum L,et al.The preparation of sub-500 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery[J]. Control Rel,2000,25(2):145.
  • 3Alenso M J,Losa C,Calvo P,et al.Approaches to improve the ass-ociation of amikacin sulphate to poly(cyanoacrylate) nanoparticles[J]. Int J Pharm,1991,68(1):69.
  • 4Couvreur P,Kante B,Roland M,et al.Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum[J]. J Pharm Sci,1979,68(17): 1521.
  • 5Radwan M A.In vitro evaluation of polyisobutylcyanoacrylate nano-particles as a controlled drug carrier for theophylline[ J]. Drug Dev Ind Pharm,1995,21(22):2371.
  • 6Egea M A,Gamisani F,Valero J,et al.Entrapment of cisplatin into biodegradable polyalkylcyanoacrylate nanoparticles[J]. Farmaco,1994,49(2): 211.
  • 7Yoo H S,Oh J E,Lee K H,et al.Biodegradable nanoparticles con-taining doxorubicin-PLGA conjugate for suatained release[J]. Pharm Res,1999,16(15): 1114.
  • 8Washington C. Drug release from microdisperse systems. a critical review[ J]. Int J Pharm, 1990,58(1): 1.
  • 9Samaligly M S,Rohdewald P,Mohmoud H A. Polyalkylcyanoacrylate nanoparticles[ J]. J Pharm Pharmacol,1986,38(3): 216.
  • 10Cavallaro G,Fresta M,Giammona G,et al.Entrapment of β-lactams antibiotics in polyethylcyanoacrylate nanoparticles: studies on the possible in vivo application of this colloidal delivery system[J]. Int J Pharm,1994,111(1): 31-41.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部